Ferring Pharmaceuticals and Enteris BioPharma Inc. recently formed a drug development partnership to to develop an oral formulation, peptide-based injectable therapeutic.
The partnership allows Ferring to develop the therapeutic utilizing Enteris’ Peptelligence, an oral peptide and small molecule
“Our agreement with Ferring Pharmaceuticals exemplifies the opportunity our Peptelligence platform offers in enhancing the market potential of peptide-based therapeutics by enabling the oral delivery of medications that must otherwise be administered by injection,” Joel Tune, CEO and executive chairman of Enteris BioPharma, said. “We are excited to work with an industry leader like Ferring Pharmaceuticals to advance the development of an oral peptide-based therapeutic.”
Enteris BioPharma prides itself on its “Feasibility-to-Licensing” strategy in regards to Peptelligence. It has been successful for a decade in providing peptide-based therapeutics and other molecules that have low bioavailability.
“The ability to deliver oral peptides offers Ferring the opportunity to provide additional therapeutic choices to patients,” Alan Harris, senior vice president of the Research and Development Executive Office of Ferring Pharmaceuticals, said. "We are impressed with Enteris’ proprietary oral delivery technology and look forward to working with them to advance this development program.”
Ferring, Enteris ink deal to develop oral peptide formula